273 related articles for article (PubMed ID: 16244317)
41. Genome stability in Arabidopsis cells exhibiting alternative lengthening of telomeres.
Akimcheva S; Zellinger B; Riha K
Cytogenet Genome Res; 2008; 122(3-4):388-95. PubMed ID: 19188710
[TBL] [Abstract][Full Text] [Related]
42. Epigenetic regulation of telomeres in human cancer.
Vera E; Canela A; Fraga MF; Esteller M; Blasco MA
Oncogene; 2008 Nov; 27(54):6817-33. PubMed ID: 18762811
[TBL] [Abstract][Full Text] [Related]
43. Mutated telomeres sensitize tumor cells to anticancer drugs independently of telomere shortening and mechanisms of telomere maintenance.
Cerone MA; Londoño-Vallejo JA; Autexier C
Oncogene; 2006 Nov; 25(56):7411-20. PubMed ID: 16767163
[TBL] [Abstract][Full Text] [Related]
44. Human sarcomas are mosaic for telomerase-dependent and telomerase-independent telomere maintenance mechanisms: implications for telomere-based therapies.
Gocha AR; Nuovo G; Iwenofu OH; Groden J
Am J Pathol; 2013 Jan; 182(1):41-8. PubMed ID: 23260199
[TBL] [Abstract][Full Text] [Related]
45. Telomere configuration influences the choice of telomere maintenance pathways.
Wen WY; Tsai HJ; Lin CC; Tseng SF; Wong CW; Teng SC
Biochem Biophys Res Commun; 2006 May; 343(2):459-66. PubMed ID: 16546132
[TBL] [Abstract][Full Text] [Related]
46. Telomere instability and cancer.
Londoño-Vallejo JA
Biochimie; 2008 Jan; 90(1):73-82. PubMed ID: 17728038
[TBL] [Abstract][Full Text] [Related]
47. Telomere capping and cellular checkpoints: clues from fruit flies.
Ciapponi L; Cenci G
Cytogenet Genome Res; 2008; 122(3-4):365-73. PubMed ID: 19188707
[TBL] [Abstract][Full Text] [Related]
48. DNA damage induces alternative lengthening of telomeres (ALT) associated promyelocytic leukemia bodies that preferentially associate with linear telomeric DNA.
Fasching CL; Neumann AA; Muntoni A; Yeager TR; Reddel RR
Cancer Res; 2007 Aug; 67(15):7072-7. PubMed ID: 17652140
[TBL] [Abstract][Full Text] [Related]
49. [Mechanisms of alternative lengthening of telomeres].
Grach AA
Tsitol Genet; 2011; 45(2):69-81. PubMed ID: 21574432
[TBL] [Abstract][Full Text] [Related]
50. Telomerase inhibition by an siRNA directed against hTERT leads to telomere attrition in HT29 cells.
de Souza Nascimento P; Alves G; Fiedler W
Oncol Rep; 2006 Aug; 16(2):423-8. PubMed ID: 16820926
[TBL] [Abstract][Full Text] [Related]
51. Assaying and investigating Alternative Lengthening of Telomeres activity in human cells and cancers.
Henson JD; Reddel RR
FEBS Lett; 2010 Sep; 584(17):3800-11. PubMed ID: 20542034
[TBL] [Abstract][Full Text] [Related]
52. Short telomeres resulting from heritable mutations in the telomerase reverse transcriptase gene predispose for a variety of malignancies.
Hills M; Lansdorp PM
Ann N Y Acad Sci; 2009 Sep; 1176():178-90. PubMed ID: 19796246
[TBL] [Abstract][Full Text] [Related]
53. Telomere length homeostasis requires that telomerase levels are limiting.
Cristofari G; Lingner J
EMBO J; 2006 Feb; 25(3):565-74. PubMed ID: 16424902
[TBL] [Abstract][Full Text] [Related]
54. Critically short telomeres in acute myeloid leukemia with loss or gain of parts of chromosomes.
Swiggers SJ; Kuijpers MA; de Cort MJ; Beverloo HB; Zijlmans JM
Genes Chromosomes Cancer; 2006 Mar; 45(3):247-56. PubMed ID: 16281260
[TBL] [Abstract][Full Text] [Related]
55. Telomerase: cellular immortalization and neoplastic transformation. Multiple functions of a multifaceted complex.
Belgiovine C; Chiodi I; Mondello C
Cytogenet Genome Res; 2008; 122(3-4):255-62. PubMed ID: 19188694
[TBL] [Abstract][Full Text] [Related]
56. Pharmacological intervention strategies for affecting telomerase activity: future prospects to treat cancer and degenerative disease.
Tárkányi I; Aradi J
Biochimie; 2008 Jan; 90(1):156-72. PubMed ID: 17945408
[TBL] [Abstract][Full Text] [Related]
57. Budding yeast with human telomeres: a puzzling structure.
Auriche C; Di Domenico EG; Ascenzioni F
Biochimie; 2008 Jan; 90(1):108-15. PubMed ID: 17954006
[TBL] [Abstract][Full Text] [Related]
58. Telomerase inhibition and telomere targeting in hematopoietic cancer cell lines with small non-nucleosidic synthetic compounds (BIBR1532).
El Daly H; Martens UM
Methods Mol Biol; 2007; 405():47-60. PubMed ID: 18369817
[TBL] [Abstract][Full Text] [Related]
59. Targeting the limitless replicative potential of cancer: the telomerase/telomere pathway.
Kelland L
Clin Cancer Res; 2007 Sep; 13(17):4960-3. PubMed ID: 17785545
[TBL] [Abstract][Full Text] [Related]
60. Alternative lengthening of telomeres does exist in various canine sarcomas.
Kreilmeier T; Sampl S; Deloria AJ; Walter I; Reifinger M; Hauck M; Borst LB; Holzmann K; Kleiter M
Mol Carcinog; 2017 Mar; 56(3):923-935. PubMed ID: 27585244
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
